Longevity Health (NASDAQ:XAGE) vs. Check-Cap (NASDAQ:MBAI) Head to Head Review

Longevity Health (NASDAQ:XAGE) and Check-Cap (NASDAQ:MBAI) are both small-cap manufacturing companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Longevity Health and Check-Cap’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Check-Cap	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Longevity Health and Check-Cap, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0	0	0	0	0.00
Check-Cap	1	0	0	0	1.00

Volatility & Risk

Longevity Health has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Check-Cap has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Institutional and Insider Ownership

24.2% of Longevity Health shares are owned by institutional investors. Comparatively, 1.1% of Check-Cap shares are owned by institutional investors. 29.0% of Longevity Health shares are owned by company insiders. Comparatively, 0.5% of Check-Cap shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Longevity Health and Check-Cap”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05 million	0.47	-$10.37 million	($3.91)	-0.07
Check-Cap	N/A	N/A	-$25.15 million	($2.77)	-0.59

Longevity Health has higher revenue and earnings than Check-Cap. Check-Cap is trading at a lower price-to-earnings ratio than Longevity Health, indicating that it is currently the more affordable of the two stocks.

About Longevity Health

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.